Exclusive: Biogen president fears CMS will finalize restrictive coverage decision for Aduhelm, preps plans to flood NCD with comments

Zachary Brennan

Senior Editor

While lamenting yesterday’s proposed national coverage decision for its controversial Alzheimer’s drug, Biogen’s US president Alisha Alaimo pledged to flood CMS with comments over the next 30 days in an attempt to ensure the final version does not reflect Tuesday’s draft, according to an internal email reviewed by Endpoints News.

“We were prepared for the range of scenarios. Unfortunately, this is one of the most restrictive options CMS could have chosen,” Alaimo said in an email to staff on Wednesday. “If this draft becomes final in April, it will significantly limit Medicare reimbursement for Aduhelm and future therapies in this class.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Biogen president fears CMS will finalize restrictive coverage decision for Aduhelm, preps plans to flood NCD with comments

Zachary Brennan

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

Data Quality 2.0: The Future of Real-World Evidence

Ex­clu­sive: Bio­gen pres­i­dent fears CMS will fi­nal­ize re­stric­tive cov­er­age de­ci­sion for Aduhelm, preps plans to flood NCD with com­ments

Zachary Brennan

Senior Editor

Unlock this article instantly by becoming a free subscriber.

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

Exclusive: Biogen president fears CMS will finalize restrictive coverage decision for Aduhelm, preps plans to flood NCD with comments

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

FDA unveils new rare disease pilot program to increase agency-sponsor communications

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

Data Quality 2.0: The Future of Real-World Evidence